AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9182212 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin (initial bolus of 100 U per kilogram)
Number of subjects: 2792
Study 9182212 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard-dose heparin (initial bolus of 100 U per kilogram)
Number of subjects: 2792
Study 7894540 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (therapeutic doses)
Number of subjects: 0
Study 7894540 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions (no specific intervention mentioned)
Number of subjects: 0
Study 3675133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of ethanol
Number of subjects: 30
Study 3675133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mL/kg of ethanol
Number of subjects: 30
Study 3675133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31603281 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya lecithin (1.5 g per day) in a custom-made biscuit
Number of subjects: 20
Study 31603281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29222809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm abutment
Number of subjects: 22
Study 29222809 — intervention group
Group type: COMPARATOR
Intervention: 3 mm abutment
Number of subjects: 22
Study 28551778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 5928
Study 25673440 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai capsule (4 capsules tid, po for 12 weeks)
Number of subjects: 90
Study 25673440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg qd, po for 12 weeks)
Number of subjects: 90
Study 25673440 — intervention group
Group type: COMPARATOR
Intervention: Blank Control (no drug addition)
Number of subjects: 90
Study 23987657 — intervention group
Group type: EXPERIMENTAL
Intervention: Online palliative care education
Number of subjects: 169
Study 23987657 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 169
Study 20888993 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (chemotherapy started within 28 days of increased CA125 measurement)
Number of subjects: 529
Study 20888993 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (chemotherapy commenced at clinical or symptomatic relapse)
Number of subjects: 529
Study 20888993 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (primary outcome)
Number of subjects: 529
Study 18172907 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 mg)
Number of subjects: 8
Study 18172907 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine IR (75 mg)
Number of subjects: 8
Study 18172907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16955451 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong practice for 16 weeks
Number of subjects: 82
Study 16955451 — intervention group
Group type: COMPARATOR
Intervention: Newspaper reading group for 16 weeks
Number of subjects: 82
Study 12714152 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 76
Study 12714152 — intervention group
Group type: COMPARATOR
Intervention: Inactive pacing (sinus rhythm group)
Number of subjects: 76
Study 12714152 — intervention group
Group type: COMPARATOR
Intervention: Ventricular-inhibited pacing (atrial fibrillation group)
Number of subjects: 76
Study 10939428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with PEM regimen: cisplatin 60 mg/m2, etoposide 40 mg/m2, mitomycin-C 7 mg/m2
Number of subjects: 32
Study 10939428 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 32
Study 8755686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg, once daily
Number of subjects: 34
Study 8755686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1584996 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of mifepristone (RU 486)
Number of subjects: 20
Study 1584996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin with Ethambutol
Number of subjects: 513
Study 3937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin with Pyrazinamide
Number of subjects: 513
Study 3937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin without a third drug
Number of subjects: 513
Study 3937189 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 513
Study 3937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 513
Study 3937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 513
Study 29704965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBT‐ST)
Number of subjects: 44
Study 29704965 — intervention group
Group type: COMPARATOR
Intervention: Activities‐Based Support Group (ASG)
Number of subjects: 44
Study 29704965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DBT‐ST and ASG
Number of subjects: 44
Study 27445162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamylated albumin concentration measurement at dialysis initiation and every subsequent 90-day period until 1 year or death
Number of subjects: 366
Study 27445162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamylated albumin concentration modeling for mortality prediction
Number of subjects: 366
Study 25443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring model developed from identified risk factors (amount of contrast, diabetes with microangiopathy, hypotension, peripheral vascular disease, albuminuria, glomerular filtration rate (GFR), anemia)
Number of subjects: 1200
Study 25443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring model
Number of subjects: 1200
Study 25443605 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 1200
Study 22111654 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive maintenance (GTP; n = 39)
Number of subjects: 80
Study 22111654 — intervention group
Group type: COMPARATOR
Intervention: No preventive maintenance (GNTP; n = 41)
Number of subjects: 80
Study 22111654 — intervention group
Group type: EXPERIMENTAL
Intervention: Global sample
Number of subjects: 80
Study 20728709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30
Study 20728709 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30
Study 20728709 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 18182617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887
Study 18182617 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887
Study 18182617 — intervention group
Group type: COMPARATOR
Intervention: Control arms (sequential control: four cycles of doxorubicin at 75 mg/m2, followed by three cycles of CMF; concurrent control: four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887
Study 18182617 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment (both sequential and concurrent)
Number of subjects: 2887
Study 15794970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip spica group
Number of subjects: 108
Study 15794970 — intervention group
Group type: COMPARATOR
Intervention: External fixation group
Number of subjects: 108
Study 11911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally guided self-care programme
Number of subjects: 169
Study 11911510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 10407836 — intervention group
Group type: EXPERIMENTAL
Intervention: First episode schizophrenia
Number of subjects: 66
Study 10407836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 66
Study 10407836 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 66
Study 7478682 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (30 micrograms/h)
Number of subjects: 85
Study 7478682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 2331957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg four times a day
Number of subjects: 73
Study 2331957 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 400 mg four times a day
Number of subjects: 73
Study 2331957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and Cimetidine
Number of subjects: 73
Study 2331957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 73
Study 2331957 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 73
Study 95715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral finger movements
Number of subjects: 19
Study 95715 — intervention group
Group type: COMPARATOR
Intervention: Unilateral right-sided finger movements
Number of subjects: 19
Study 31799782 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 47
Study 31799782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30783794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 4
Study 30783794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 4
Study 30783794 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 4
Study 30783794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 25 mg
Number of subjects: 4
Study 28625962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Sparing Radical Hysterectomy (NSRH)
Number of subjects: 30
Study 28625962 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radical Hysterectomy (CRH)
Number of subjects: 30
Study 25016597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (3.05 g/day)
Number of subjects: 33
Study 25016597 — intervention group
Group type: COMPARATOR
Intervention: Typical Australian diet (23.7 g/day)
Number of subjects: 33
Study 22944373 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 99
Study 22944373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 22013171 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetic risk results counseling intervention
Number of subjects: 0
Study 22013171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower genetic risk results counseling intervention
Number of subjects: 0
Study 22013171 — intervention group
Group type: COMPARATOR
Intervention: Untested controls
Number of subjects: 0
Study 19462696 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class III-IV patients
Number of subjects: 0
Study 19462696 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) and Depression measures
Number of subjects: 0
Study 19462696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning measures
Number of subjects: 0
Study 17925871 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (0.75 mg/kg primaquine)
Number of subjects: 108
Study 17925871 — intervention group
Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 108
Study 17925871 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AS+PQ
Number of subjects: 108
Study 10849921 — intervention group
Group type: EXPERIMENTAL
Intervention: Active feedback via practice visits from the pharmaceutical prescribing adviser
Number of subjects: 66
Study 10849921 — intervention group
Group type: COMPARATOR
Intervention: Passive feedback via practice specific prescribing analysis workbook
Number of subjects: 66
Study 10849921 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no feedback)
Number of subjects: 66
Study 8973990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin HCL 1,700 mg (single dose)
Number of subjects: 18
Study 8973990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin HCL 850 mg (multiple doses, 3 times daily for 19 doses)
Number of subjects: 18
Study 8973990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8973990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin HCL (single and multiple doses) in healthy subjects
Number of subjects: 18
Study 1453750 — intervention group
Group type: EXPERIMENTAL
Intervention: D860 plus Tong Yu Ling (TYL)
Number of subjects: 72
Study 1453750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Yu Ling (TYL) alone
Number of subjects: 72
Study 1453750 — intervention group
Group type: COMPARATOR
Intervention: D860 alone
Number of subjects: 72
Study 6085386 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mg nitrendipine tablet
Number of subjects: 22
Study 6085386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg nitrendipine tablet
Number of subjects: 22
Study 6085386 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mg nitrendipine tablet
Number of subjects: 22
Study 6085386 — intervention group
Group type: COMPARATOR
Intervention: Liquid suspension of nitrendipine
Number of subjects: 22
Study 6085386 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses (5‐mg, 10‐mg, 20‐mg)
Number of subjects: 22
Study 6085386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and its metabolites
Number of subjects: 22
Study 31215773 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 31215773 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0
Study 30046610 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at ST36-ST37, 20 minutes twice a day for five days
Number of subjects: 71
Study 30046610 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies including fluid resuscitation, anti‐infection, vasoactive agents, mechanical ventilation, supply of enteral nutrition, and glutamine
Number of subjects: 71
Study 27479098 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT)
Number of subjects: 0
Study 27479098 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 0
Study 27479098 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT) with a supportive person
Number of subjects: 0
Study 27479098 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT) without a supportive person
Number of subjects: 0
Study 25269885 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin XR 5/500 mg FDC tablet
Number of subjects: 64
Study 25269885 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin XR 5/1,000 mg FDC tablet
Number of subjects: 64
Study 25269885 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of saxagliptin and metformin XR
Number of subjects: 64
Study 22257600 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted BLS (with software assistance)
Number of subjects: 141
Study 20195158 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release melatonin (6 mg) given at bedtime for 4 weeks
Number of subjects: 33
Study 20195158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18343246 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg (titrated to 8 mg if needed)
Number of subjects: 60
Study 18343246 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (titrated to 100 mg if needed)
Number of subjects: 60
Study 18343246 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 60
Study 18343246 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60
Study 18343246 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and Atenolol
Number of subjects: 60
Study 16134134 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited (D1) lymph node dissection
Number of subjects: 0
Study 16134134 — intervention group
Group type: COMPARATOR
Intervention: Extended (D2) lymph node dissection
Number of subjects: 0
Study 12075268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with carnitine, CoQ10, and taurine
Number of subjects: 41
Study 12075268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 12075268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 41
Study 10633314 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with borderline personality disorder (BPD)
Number of subjects: 62
Study 10633314 — intervention group
Group type: COMPARATOR
Intervention: Women with histories of childhood sexual abuse (no BPD)
Number of subjects: 62
Study 10633314 — intervention group
Group type: COMPARATOR
Intervention: Women with no history of sexual abuse or BPD
Number of subjects: 62
Study 8546658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone combined with gemeprost (prostaglandin analogue)
Number of subjects: 20
Study 8546658 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone alone
Number of subjects: 20
Study 8546658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone combined with gemeprost
Number of subjects: 20
Study 1958475 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan and thioguanine
Number of subjects: 675
Study 1958475 — intervention group
Group type: COMPARATOR
Intervention: Busulphan alone
Number of subjects: 675
Study 31466022 — intervention group
Group type: COMPARATOR
Intervention: DBS leads inserted using conventional landmarks (Group A)
Number of subjects: 34
Study 31466022 — intervention group
Group type: EXPERIMENTAL
Intervention: Leads guided into the DRTT using DTIT (Group B)
Number of subjects: 34
Study 30409962 — intervention group
Group type: EXPERIMENTAL
Intervention: XPD siRNA
Number of subjects: 0
Study 30409962 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 inhibitor (1 μM bpV)
Number of subjects: 0
Study 30409962 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (NC)
Number of subjects: 0
Study 25987674 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child interactive intervention
Number of subjects: 75
Study 25987674 — intervention group
Group type: COMPARATOR
Intervention: Written materials on tobacco hazards (Control)
Number of subjects: 75
Study 24556289 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention for the management of osteoarthritis
Number of subjects: 14
Study 22351883 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare (SC) model for child neglect
Number of subjects: 2175
Study 22351883 — intervention group
Group type: COMPARATOR
Intervention: Comparable home-based services without SC modules (Control)
Number of subjects: 2175
Study 20028464 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (sham acupuncture)
Number of subjects: 0
Study 20028464 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (waitlist)
Number of subjects: 0
Study 18556085 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Yale insulin infusion protocol (MY group)
Number of subjects: 75
Study 18556085 — intervention group
Group type: COMPARATOR
Intervention: Empirical blood glucose control (EC group)
Number of subjects: 75
Study 15821487 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists (GnRH-A)
Number of subjects: 80
Study 12356612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 672
Study 12356612 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 672
Study 10487267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg orally twice daily
Number of subjects: 45
Study 10487267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally three times daily
Number of subjects: 45
Study 10487267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9081556 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus plus 10 mg of cyclophosphamide
Number of subjects: 10
Study 9081556 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (unconditioned stimulus)
Number of subjects: 10
Study 1936485 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 tabs/d, i.e. 1,700 mg/d)
Number of subjects: 400
Study 1936485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tabs/d)
Number of subjects: 400
Study 6217028 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (30-40-30 micrograms EE and 50-75-125 micrograms levonorgestrel)
Number of subjects: 193
Study 6217028 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose oral contraceptive (30 micrograms EE and 150 micrograms desogestrel)
Number of subjects: 193
Study 6217028 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 193
Study 6217028 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose oral contraceptive
Number of subjects: 193
Study 6217028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 193
Study 31552500 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain oats cooked under normal pressure (WONP)
Number of subjects: 10
Study 31552500 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain oats cooked under higher pressure (WOHP)
Number of subjects: 10
Study 31552500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearled oats cooked under normal pressure (PONP)
Number of subjects: 10
Study 31552500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearled oats cooked under higher pressure (POHP)
Number of subjects: 10
Study 31552500 — intervention group
Group type: COMPARATOR
Intervention: Oat-rice mixed meals (OG + R) including WONP + R, WOHP + R, PONP + R, POHP + R
Number of subjects: 10
Study 31552500 — intervention group
Group type: EXPERIMENTAL
Intervention: WONP + R
Number of subjects: 10
Study 31552500 — intervention group
Group type: COMPARATOR
Intervention: Oat-rice mixed meals (OG + R)
Number of subjects: 10